F18.29
Inhalant dependence with unspecified inhalant-induced disorder
Clinical Classification Guidelines
Medical Intelligence & Overview
Inhalant dependence with unspecified inhalant-induced disorder (ICD-10 Code F18.29) refers to a substance use condition where an individual is addicted to inhalants—substances that are sniffed or inhaled to achieve a psychoactive effect. This disorder involves both a psychological and physical dependence on inhalants, leading to significant health issues. Inhalants include a diverse range of substances such as solvents, aerosols, gases, and nitrites. These substances are often household products or common items misused for their intoxicating effects. Because of the broad range of chemicals involved, this diagnosis is used when the specific inhalant cannot be detailed.
Causes & Symptoms
Clinical Causes: Repeated exposure to household or recreational inhalants such as glue, paint thinners, aerosols, or cleaning agents. Behavioral factors like peer pressure, curiosity during adolescence, or a desire to escape from stress or emotional issues. Lack of awareness about the risks associated with inhalant use. Availability and accessibility of inhalants in the environment or community. Underlying mental health conditions, including anxiety or depression, which may increase susceptibility. Familial or social environments that normalize or fail to discourage inhalant use.
Key Symptoms: Craving or a strong desire to use inhalants. Inability to stop or control inhalant use despite negative consequences. Preoccupation with obtaining and using inhalants. Neglect of responsibilities at work, school, or home. Physical signs such as chemical odors, paint or chemical stains on the face or clothing, or respiratory problems. Behavioral changes including dizziness, lack of coordination, or confusion. Mood swings, irritability, or signs of withdrawal when not using inhalants. Engaging in risky behaviors or accidents due to impaired judgment.
Diagnostic & Treatment
Diagnosis Path: Diagnosis generally involves a comprehensive clinical assessment by a healthcare professional, including understanding usage patterns, physical examination, and sometimes laboratory testing. Medical history and behavioral observations help confirm inhalant dependence. Because inhalants are often household products, disclosure can be challenging, and careful interviewing techniques are necessary. In some cases, toxicology screens may detect inhalant metabolites or chemical residues.
Treatment Protocols: Managing inhalant dependence requires a multidisciplinary approach. Treatment strategies may include: - **Detoxification:** Supervised withdrawal to manage acute physical symptoms. - **Behavioral therapy:** Counseling to address underlying psychological factors and develop coping skills. - **Educational programs:** To increase awareness of inhalant dangers and promote avoidance. - **Support groups:** Providing peer support and ongoing motivation. - **Treatment of physical health issues:** Addressing respiratory problems, neurological effects, or other medical conditions caused by inhalant use. - **Family therapy:** Involving family members to support recovery and address environmental influences. Timely intervention is vital to prevent long-term health consequences.
Clinical Advice & FAQs
Billing Guidance
Is F18.29 a billable ICD-10 code?
Yes, F18.29 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F18.29?
Clinical documentation must specify the nature of Inhalant dependence with unspecified inhalant-induced disorder and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
